Xeris Biopharma (NASDAQ:XERS) Insider Kevin Mcculloch Sells 90,000 Shares of Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Kevin Mcculloch sold 90,000 shares of the company’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $8.03, for a total transaction of $722,700.00. Following the completion of the transaction, the insider owned 1,691,126 shares in the company, valued at $13,579,741.78. This trade represents a 5.05% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Xeris Biopharma Stock Performance

NASDAQ XERS opened at $8.28 on Friday. The company has a quick ratio of 1.50, a current ratio of 2.12 and a debt-to-equity ratio of 17.00. The company has a market capitalization of $1.43 billion, a P/E ratio of 138.00 and a beta of 0.62. Xeris Biopharma Holdings, Inc. has a 12-month low of $4.62 and a 12-month high of $10.08. The firm has a 50-day moving average price of $6.56 and a two-hundred day moving average price of $6.62.

Xeris Biopharma (NASDAQ:XERS) last announced its earnings results on Thursday, May 7th. The company reported $0.01 earnings per share (EPS) for the quarter. Xeris Biopharma had a net margin of 3.81% and a return on equity of 735.00%. The firm had revenue of $83.13 million for the quarter, compared to analyst estimates of $79.83 million. Analysts anticipate that Xeris Biopharma Holdings, Inc. will post 0.12 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on the company. Wall Street Zen upgraded Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a research note on Saturday, March 7th. Weiss Ratings lowered Xeris Biopharma from a “hold (c-)” rating to a “sell (d+)” rating in a report on Monday, May 11th. Four investment analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $10.80.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently modified their holdings of the business. UBS Group AG raised its stake in Xeris Biopharma by 682.4% during the third quarter. UBS Group AG now owns 1,782,734 shares of the company’s stock worth $14,511,000 after acquiring an additional 1,554,869 shares in the last quarter. Vanguard Group Inc. boosted its stake in shares of Xeris Biopharma by 13.8% in the 4th quarter. Vanguard Group Inc. now owns 11,186,677 shares of the company’s stock valued at $87,815,000 after purchasing an additional 1,358,760 shares in the last quarter. Qube Research & Technologies Ltd boosted its stake in shares of Xeris Biopharma by 67.5% in the 2nd quarter. Qube Research & Technologies Ltd now owns 3,089,771 shares of the company’s stock valued at $14,429,000 after purchasing an additional 1,245,188 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Xeris Biopharma by 75.4% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,790,014 shares of the company’s stock valued at $15,317,000 after purchasing an additional 1,199,435 shares during the last quarter. Finally, Granahan Investment Management LLC grew its holdings in shares of Xeris Biopharma by 249.4% during the 4th quarter. Granahan Investment Management LLC now owns 1,223,404 shares of the company’s stock valued at $9,604,000 after purchasing an additional 873,236 shares during the last quarter. Institutional investors and hedge funds own 42.75% of the company’s stock.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.